About $20 billion in partnership deal value was committed to biotech last year, with about three-quarters of the dollars coming from pharmaceutical companies. Since 2004, the number of biotech deals has fallen somewhat, whereas value has bloomed. Deals for candidates at either end of the development pipeline were particularly popular last year, with more partnerships aimed at cancer, nervous system disorders and infectious diseases.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lawrence, S. Partnerships remain buoyant. Nat Biotechnol 26, 602 (2008). https://doi.org/10.1038/nbt0608-602
Issue Date:
DOI: https://doi.org/10.1038/nbt0608-602